Search Results - "Meng, Yanchun"

Refine Results
  1. 1

    Dimer targeting peptide mediated precise and controllable drug delivery by upconversion nanocarriers for breast cancer therapy by Zhang, Kunyu, Wan, Zhong, Jiang, Huabo, Xiao, Xiufeng, Feng, Qian, Meng, Yanchun, Yu, Yongsheng

    Published in Materials & design (01-05-2021)
    “…Breast cancer is one of the leading causes of cancer-related deaths in women. Chemotherapy remains one of the main clinical treatments for breast cancer…”
    Get full text
    Journal Article
  2. 2

    MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells by Du, Yiqun, Zhang, Jian, Meng, Yanchun, Huang, Mingzhu, Yan, Wangjun, Wu, Zhiqiang

    Published in AMB Express (31-07-2020)
    “…MicroRNAs (miRs) have shown tremendous potential to act as therapeutic targets for cancer treatment. In this context, the present study was designed to…”
    Get full text
    Journal Article
  3. 3

    Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation by Tang, Qiqi, Liang, Beibei, Zhang, Lisha, Li, Xuhui, Li, Hengyu, Jing, Wei, Jiang, Yingjie, Zhou, Felix, Zhang, Jian, Meng, Yanchun, Yang, Xinhua, Yang, Hao, Huang, Gang, Zhao, Jian

    Published in Scientific reports (17-10-2022)
    “…Neutrophil extracellular traps (NETs) has been demonstrated to regulate the metastasis of breast cancer. In this study, we showed that de novo cholesterol…”
    Get full text
    Journal Article
  4. 4

    Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data by Zhang, Xiaowei, Jin, Feng, Jiang, Shiyu, Cao, Jun, Meng, Yanchun, Xu, Yu, ChunmengWang, Chen, Yong, Yang, Huijuan, Kong, Yunyi, Liu, Xin, Luo, Zhiguo

    Published in Investigational new drugs (01-04-2022)
    “…Summary Background. Mucosal melanoma is rare and has distinct clinical and genetic features. Even with advances in targeted and immune therapies, the survival…”
    Get full text
    Journal Article
  5. 5

    Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer by Mu, Yuxin, Meng, Yanchun, Du, Yiqun, Liu, Xiaojun, Zhang, Jian

    Published in Thoracic cancer (01-12-2023)
    “…Background The clinical characteristics and efficacy of human epidermal growth factor receptor‐2 (HER‐2)‐directed agents against HER2 mutations and HER2…”
    Get full text
    Journal Article
  6. 6

    Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors by Liu, Rujiao, Li, Wenhua, Meng, Yanchun, Gao, Shuiping, Zhang, Jian, Hu, Xichun

    “…Background: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge…”
    Get full text
    Journal Article
  7. 7

    The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors by Li, Wei, Li, Jinfeng, Gao, Jie, Li, Bohua, Xia, Yu, Meng, Yanchun, Yu, Yongsheng, Chen, Huaiwen, Dai, Jianxin, Wang, Hao, Guo, Yajun

    Published in Biomaterials (01-05-2011)
    “…Abstract Focusing on high temperature and low pH of tumor tissue, we prepared temperature and pH responsive poly(N-isopropylacrylamide- co…”
    Get full text
    Journal Article
  8. 8

    The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes by Gao, Jie, Liu, Wei, Xia, Yu, Li, Wei, Sun, Jing, Chen, Huaiwen, Li, Bohua, Zhang, Dapeng, Qian, Weizhu, Meng, Yanchun, Deng, Li, Wang, Hao, Chen, Jianming, Guo, Yajun

    Published in Biomaterials (01-05-2011)
    “…Abstract The LPD (liposome-polycation-DNA complex) is an effective nanovector for systemically small interfering RNA (siRNA) delivery which was well…”
    Get full text
    Journal Article
  9. 9

    Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study by Zhang, Jian, Meng, Yanchun, Wang, Biyun, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Li, Ting, Yao, Wenqing, Hu, Xichun

    Published in Frontiers in oncology (07-03-2022)
    “…The LORDSHIPS study aimed to explore the safety and efficacy of a novel fully oral triplet combination of dalpiciclib (a potent cyclin-dependent kinase 4/6…”
    Get full text
    Journal Article
  10. 10

    Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors by Li, Zhaoliang, Meng, Yanchun, Xu, Shengtao, Shen, Wang, Meng, Zhaoqing, Wang, Zhenzhong, Ding, Gang, Huang, Wenzhe, Xiao, Wei, Xu, Jinyi

    Published in Bioorganic & medicinal chemistry (15-05-2017)
    “…[Display omitted] In search of novel anti-influenza agents with higher potency, a series of acylguanidine oseltamivir carboxylate analogues were synthesized…”
    Get full text
    Journal Article
  11. 11

    Transit-Oriented Development in China: A Comparative Content Analysis of the Spatial Plans of High-Speed Railway Station Areas by Wang, Biyue, de Jong, Martin, van Bueren, Ellen, Ersoy, Aksel, Meng, Yanchun

    Published in Land (Basel) (01-09-2023)
    “…With rapid high-speed railway (HSR) developments in China, HSR-based transit-oriented development (TOD) has proliferated across the country. Although local…”
    Get full text
    Journal Article
  12. 12

    Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours by Zhang, Jian, Liu, Rujiao, Gao, Shuiping, Li, Wenhua, Chen, Yang, Meng, Yanchun, Liu, Chang, Jin, Wenyue, Wu, Junyan, Wang, Ying, Hao, Yanrong, Yi, Shuli, Qing, Yan, Ge, Junyou, Hu, Xichun

    Published in NPJ breast cancer (18-04-2023)
    “…In this phase I study, the safety, pharmacokinetics, and antitumour activity of the HER2-targeted antibody–drug conjugate A166 were evaluated in patients with…”
    Get full text
    Journal Article
  13. 13

    Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization by Li, Bohua, Meng, Yanchun, Zheng, Lei, Zhang, Xunmin, Tong, Qing, Tan, Wenlong, Hu, Shi, Li, Hui, Chen, Yang, Song, Jinjing, Zhang, Ge, Zhao, Lei, Zhang, Dapeng, Hou, Sheng, Qian, Weizhu, Guo, Yajun

    Published in Cancer research (Chicago, Ill.) (01-11-2013)
    “…The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer. However, resistance to trastuzumab is common…”
    Get full text
    Journal Article
  14. 14

    Molecular architecture of the ErbB2 extracellular domain homodimer by Hu, Shi, Sun, Yuna, Meng, Yanchun, Wang, Xiaoze, Yang, Weili, Fu, Wenyan, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Li, Bohua, Rao, Zihe, Lou, Zhiyong, Guo, Yajun

    Published in Oncotarget (30-01-2015)
    “…Human epidermal growth factor receptors (HERs or ErbBs) play crucial roles in numerous cellular processes. ErbB2 is a key member of ErbB family, and its…”
    Get full text
    Journal Article
  15. 15

    First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors by Zhang, Jian, Du, Yiqun, Meng, Yanchun, Liu, Xiaojun, Mu, Yuxin, Liu, Yunpeng, Shi, Yehui, Wang, Jufeng, Zang, Aimin, Gu, Shanzhi, Liu, Tianshu, Zhou, Huan, Guo, Hongqian, Xiang, Silong, Zhang, Xialu, Wu, Suqiong, Qi, Huanhuan, Li, Mengke, Hu, Xichun

    Published in NPJ precision oncology (12-09-2024)
    “…DP303c is a HER2-targeted ADC with a cleavable linker-MMAE payload. Previous in vitro studies demonstrated that DP303c showed similar or better antitumor…”
    Get full text
    Journal Article
  16. 16

    A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth by Zhang, Yajun, Wang, Lingfei, Chong, Xiaodan, Yu, Xiaojie, Meng, Yanchun, Dong, Jian, Wang, Chao, Wang, Huajing, Yang, Yang, Xia, Tian, Zhao, Jian, Li, Bohua

    “…The anti-ErbB2 humanized antibody trastuzumab was approved for ErbB2-positive metastatic gastric and gastro-esophageal junction cancer in 2010. Despite the…”
    Get full text
    Journal Article
  17. 17

    The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer by Han, Siqi, Meng, Yanchun, Tong, Qing, Li, Guangchao, Zhang, Xunmin, Chen, Yalin, Hu, Shi, Zheng, Lei, Tan, Wenlong, Li, Hui, Chen, Yang, Zhang, Ge, Li, Bohua, Guo, Yajun

    Published in mAbs (01-03-2014)
    “…The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in ErbB2-overexpressing breast and gastric cancer, but resistance to the drug is…”
    Get full text
    Journal Article
  18. 18

    Research on the hierarchical structure of the metropolitan system and economic development of the provincial capital urban circle in Shandong by Qiao, Xiaoyong, Meng, Yanchun, Zhu, Xiangyu

    “…Regional development is the trend for future urbanization,and the urban circle is a highly efficient economic spatial pattern of regional development.This…”
    Get full text
    Journal Article
  19. 19

    Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting by Mu, Yuxin, Meng, Yanchun, Zhang, Jian

    Published in Journal of clinical oncology (01-06-2024)
    “…e13013 Background: Inetetamab is a novel recombinant humanized anti-human epidermal growth factor receptor-2 (HER-2) monoclonal antibody. This real-world…”
    Get full text
    Journal Article
  20. 20